Immuneering Corporation (IMRX)
NASDAQ: IMRX
· Real-Time Price · USD
2.53
-0.24 (-8.66%)
At close: Jun 20, 2025, 3:59 PM
2.48
-2.15%
After-hours: Jun 20, 2025, 05:56 PM EDT
-8.66% (1D)
| Bid | 2.48 |
| Market Cap | 91.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -61.77M |
| EPS (ttm) | -1.97 |
| PE Ratio (ttm) | -1.29 |
| Forward PE | -1.66 |
| Analyst | Buy |
| Ask | 2.54 |
| Volume | 4,524,936 |
| Avg. Volume (20D) | 826,038 |
| Open | 2.96 |
| Previous Close | 2.77 |
| Day's Range | 2.40 - 3.06 |
| 52-Week Range | 1.00 - 3.83 |
| Beta | 0.00 |
About IMRX
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol IMRX
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for IMRX stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 days ago
-23.21%
Immuneering shares are trading lower. The company ...
Unlock content with
Pro Subscription
5 days ago
+24.74%
Immuneering shares are trading higher after the company announced it will provide updates from its Phase 2a clinical trial of IMM-1-104 in first-line pancreatic cancer patients.
